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LETTERS TO THE EDITOR
A comment on ‘the risk of coronary heart disease in type 2
diabetic patients exposed to thiazolidinediones compared to
metformin and sulfonylurea therapy’y
To the Editor
We read with interest the recently published article by
Johannes et al.1 evaluating whether the risk of coronary heart
disease differs among type 2 diabetic patients treated with
thiazolidinediones (TZDs) compared to those treated with
combined oral metformin and sulfonylurea (Mþ S) therapy.
This report represents an important contribution to the field,
but we would like to comment on some of the authors’
methods.
Our primary concern with this study is the definition of
study population. Although, according to the title and the
introduction, the targeted study population was type 2
diabetic patients, it is not clear that Johannes et al.1 excluded
type 1 diabetic patients and specifically selected type 2
diabetic patients.
Although type 1 diabetes mellitus most commonly
develops before the age of 30,2 in contrast to previous
studies targeting type 2 diabetic patients,3,4 the authors did
not include information regarding how patients with type 1
diabetes were excluded which is especially important in the
case of patients under the age of 35. Moreover, a previous
study observed that the majority of cases of death in diabetic
participants was attributable to acute coronary events, and
that the 5-year mortality rate for type 2 diabetes (18.9%) was
higher than that for type 1 (5.5%).4 Likewise, type 1 and type
2 diabetes may differ in several aspects, such as their
complications. Therefore, the authors should give details of
the criteria of the study population.
Another concern is that among 12570 TZD initiators, in
the ‘as balanced’ analyses, 56% began TZD monotherapy,
16% added a TZD to metformin, 22% added a TZD to
sulfonylurea and 6% added a TZD to combination Mþ S
therapy; only 38% remained on TZD monotherapy
throughout the study period.1 This leaves us wondering
how different the results would have been if the TZD
initiators included in the ‘as balanced’ analyses would have
been restricted to those who began TZD monotherapy,
especially to those who remained on TZD monotherapy
throughout the study period.
Our third concern with this study is that the authors did
not clearly define the non-user group. If non-use was a
substitute for ‘no exposure’, which the authors defined, it
would be helpful if a different definition were to be used
because no exposure, which the authors defined, might result
in a different outcome than that seen for patients who have
never used TZD. This leaves us wondering whether the
results would have been different for as treated analyses if
the reference group would have been defined as those who
have never used TZD.
Finally, the reason that the authors chose as the
comparison group patients receiving Mþ S therapy to
evaluate ‘the effects of TZD therapy as prescribed in routine
clinical practice on coronary heart disease in comparison
with other oral antidiabetic therapy’ remains unclear,
although authors explained that patients started on TZDs
might be more advanced in their disease progression than
diabetics started on other oral antidiabetic therapy.1 Recent
studies have shown that the combination of sulfonylureas
and metformin might result in a higher risk of adverse
cardiovascular outcomes than treatment with metformin
alone.3 In addition, different sulfonylurea derivatives could
lead to different outcomes, in particular as regards
cardiovascular outcome.5,6 Among sulfonylurea derivatives
included in final analysis, it would be helpful to include
information on what kinds of sulfonylurea derivatives were
included.
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Response to a comment on ‘the risk of coronary heart disease
in type 2 diabetic patients exposed to thiazolidinediones
compared to metformin and sulfonylurea therapy’
Dear Editor
We welcome the opportunity to respond to the letter from
Chang and colleagues1 with questions relating to our study
of the risk of coronary heart disease in patients with type 2
diabetes exposed to thiazolidinediones (TZD) compared
with metformin and sulfonylurea (Mþ S) therapy.2 To
address the primary concern about our study population
definition and whether patients with type 1 diabetes were
excluded, we would like to clarify that we defined the study
cohorts on the basis of a pharmacy claim for a dispensing of
one of the relevant oral antidiabetic drugs, not on the basis of
diagnosis codes on health services claims. Because the drugs
under investigation, the TZDs, metformin and sulfonylureas,
are only indicated for treatment of type 2 diabetes (they have
no role in the treatment of type 1 diabetes), cohorts formed
on the dispensing of these drugs will be devoid of patients
with type 1 diabetes. In addition, due to the uncertainty in
ICD-9 coding in claims data, particularly at the 5th digit
level that is required to distinguish type 1 from type 2
diabetes, selecting the cohort based on claims for dispenings
of drugs indicated only for type 2 diabetes (a TZD or Mþ S
dispensing) was a more accurate way to restrict the study
population to patients with type 2 diabetes and to a
population that is relevant for study inferences (i.e. persons
with type 2 diabetes using oral antidiabetic drugs). The fact
that few people under 30 are present in our study (less than
5%) serves as an implicit validation of our definition as it
accords with the expected low prevalence of type 2 diabetes
in this age group.3 In addition, the propensity matching
resulted in study cohorts that arewell balanced at baseline on
complications of diabetes and baseline insulin use.
Chang and coauthors were also concerned that the results
may have differed had we restricted the TZD initiators in the
‘as balanced’ analyses to monotherapy users. We would point
out that changes in therapy during follow-up are notoriously
difficult to account for because the changes in therapy may be
a function of therapy (adverse effects or therapy failure) or
may be related to changes in the patient’s underlying clinical
status. Accordingly, while it is entirely plausible that a
cohort of people who remain on TZD monotherapy
throughout follow-up may have a different risk of outcomes,
they may have a different risk of outcomes due to either a
drug effect or a selection effect. In our ‘as treated’ analyses,
we examined TZD monotherapy-exposed person–time
relative to Mþ S exposed person time and the results were
the same (IRR from Poisson regression¼ 1.02) as the results
from the as- balanced analysis: (HR from Cox proportional
hazards model¼ 1.02).2 In addition, Chang and coauthors
question what the results would have been had we used a
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